Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.

The Journal of urology - 1 Jul 2001

Chang F L, Lai M D

Abstract excerpt

PURPOSES: The nature of p53 mutation has been reported to affect cellular responses to chemotherapy. We characterized the impact of p53 mutations on drug resistance in bladder cancer cells. METHODS AND METHODS: Various human p53 mutants (V143A, V173L, H179Q, N247I and R273H) were introduced to the TCC-SUP bladder carcinoma cell line to establish stable transfectants. The expression of mutant p53 was demonstrated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Doxorubicin
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, p53

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Sensitivity and Specificity

Share to Tumor Cells, Cultured

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 11435891

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.PMID 11435891Read ↗

Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells.Semantic proximity Read ↗

Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell linesSemantic proximity Read ↗

Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.Semantic proximity Read ↗

Significance of TP53 mutation in bladder cancer disease progression and drug selectionSemantic proximity Read ↗

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.Semantic proximity Read ↗

Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cellsSemantic proximity Read ↗

Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responsesSemantic proximity Read ↗

Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.Semantic proximity Read ↗

Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells.Semantic proximity Read ↗

p53 and chemosensitivity in bladder cancer.Semantic proximity Read ↗

Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2.Semantic proximity Read ↗

Prima-1 induces apoptosis in bladder cancer cell lines by activating p53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.